The world’s first new FcRn antagonist formulation is approved for marketing in the United States

April 15, 2025  Source: drugdu 63

"/Recently, Zai Lab's partner argenx announced that the U.S. FDA (U.S. Food and Drug Administration) has officially approved the marketing of Efgartigimod prefilled subcutaneous injection formulation for the treatment of adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are positive for acetylcholine receptor (AChR) antibodies. Efgartigimod is the world's first approved FcRn antagonist. Previously, its intravenous formulation (IV) and subcutaneous formulation (SC) have been approved for marketing by the FDA (U.S. Food and Drug Administration).

The approval of the prefilled subcutaneous injection formulation further enriches the product form of Efgartigimod and improves the convenience of patients' medication. This not only consolidates Argenx's leading position in the field of FcRn antagonists, but also brings new market opportunities to Zai Lab. As Agamod continues to expand in the global market, Zai Lab is expected to share its growth dividend in the field of rare diseases through cooperation and enhance its valuation and attractiveness in the capital market.

https://finance.eastmoney.com/a/202504143375319785.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.